Pfizer’s Blockbuster Drug Lyrica Comes off Patent

Lyrica, Pfizer’s blockbuster anticonvulsive treatment, is expected to come off-patent in December 2018, leading to a dramatic reduction in sales due to generic erosion.

This will have a huge effect on Pfizer’s financial performances, with sales of Lyrica forecast to drop from $5 billion in 2018 to about $3 billion in 2019.

Lyrica, an anticonvulsive therapy prescribed for neuropathy and many other disorders, including pain associated with spinal injuries, is the top-selling drug in the central nervous system market, and the fall in sales could see Pfizer lose its stature as the top company in this sector, with Biogen in close competition.

Pfizer hoping that Lyrica CR will help mitigate losses

Lyrica CR is a new drug with the same mechanism of action as Lyrica but with an improved once-daily dosage regime.

It gained approval in late 2017 but only for shingles and diabetic peripheral neuropathy, which will limit its potential.

Generic companies waiting to pounce

Given the commercial success of Lyrica, many generic companies are eagerly awaiting Lyrica’s patent expiry.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

With several generics looking to gain approval, it does not seem long until the central nervous system market sees a significant shift.

For more insight and data, visit the GBI Research report store.